Agilent supports cancer research center
Dr Ronald A. DePinho ? president of the University of Texas MD Anderson Cancer Center (Texas, USA) ? has received an Agilent Thought Leader Award.
Dr Ronald A. DePinho — president of the University of Texas MD Anderson Cancer Center (Texas, USA) — has received an Agilent Thought Leader Award. Agilent Technologies (California, USA) will provide financial support for personnel as well as instrumentation for the center.
The work of DePinho has resulted in the development of improved cancer detection methods and cancer drug development. His research group focuses broadly on basic‑to‑translational research programmes for brain, colorectal, pancreas and prostate cancers, as well as ageing and neuro‑degeneration.
The award will support DePinho and his team in their research into reprogramming the metabolome at the initial stages of cancer. Specifically, the instrumentation will “enhance” the investigation of metabolic adaptions during the development of pancreatic cancer, according to Dr Guilio Draetta, director of the Institute for Applied Cancer Science.
Pancreatic cancer is a major concern of DePinho’s group because survival rates of patients have not significantly improved over the past two decades. Depinho said: “This technology will allow us to rapidly identify new targets that drive the formation, progression and maintenance of pancreatic cancer. Discoveries from this research will also lead to the development of effective early detection biomarkers and novel therapeutic interventions.”
Patrick Kaltenbach, Agilent VP and general manager of the Liquid Phase division, said: “We are proud to support Dr DePinho’s exciting translational research programme, which will make use of metabolomics and integrated biology workflows and solutions in biomarker discovery.”
Draetta added: “Armed with novel biomarkers, earlier diagnosis and treatment will be possible, leading to improved patient outcomes. Additional opportunities for novel therapeutic intervention will also emerge from this work.”
For more information please visit:
www.agilent.com
This story originally appeared in The Column. Click here to view that issue.
HPLC 2025 Preview: The Present and Future of Automation in Analytical Laboratories
May 22nd 2025Analytical laboratories are undergoing a fundamental transformation. In the face of increasing sample volumes, growing regulatory requirements, and the rising demand for faster, more precise, and cost-efficient analysis, optimizing laboratory processes is becoming a central focus. Automation technologies offer promising solutions in this regard. Recently, they have evolved from isolated solutions to comprehensive systems that permeate nearly all areas of laboratory practice. This development not only opens up new opportunities in terms of efficiency, data quality, and scalability but also brings technical, organizational, and personnel challenges. To successfully address these, strategic approaches are needed that consider both the technological and human dimensions of the transformation.
Quantifying Isavuconazole in Dried Blood Spots Using HPLC
May 21st 2025Isavuconazole, an antimycotic agent used to treat fungal infections, can typically be found during dried blood spot sampling. However, there are obstacles that keep it from being an ideal approach for properly determining the drug’s presence.
Separating and Quantifying Spinach Flavonoids with UHPLC–MS/MS
May 21st 2025Researchers at Baylor College of Medicine’s Children's Nutrition Research Center (Houston, Texas) developed and validated a high-throughput extraction and ultrahigh-performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS) method to separate and quantify 39 spinach flavonoid species in 11.5 min.
